The global market for cervical cancer drugs is expected to grow $ 21.29 billion in 2021 a 23.23 billion dollars in 2022 at a compound annual growth rate (CAGR) of 2.1%. The growth is mainly due to companies that have reorganized their operations and are recovering from the impact of COVID-19, which previously led to restrictive containment measures regarding social distancing, remote working and the closure of businesses. commercial activities that have resulted in operational challenges. The market is expected to catch up $ 30.95 billion in 2026 at a CAGR of 7.4%.
Major players in the cervical cancer drug market are F. Hoffmann-La Roche Ltd, Hetero, GlaxoSmithKline, Eli Lilly and Company, Pfizer, Alnylam Pharmaceuticals, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company, and Novartis AG.
North America is the largest region in the cervical cancer drug market in 2021. Middle East it is expected to be the fastest growing region over the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa.
The growing prevalence of HIV (human immunodeficiency virus) in women is driving the growth of the cervical cancer drug market. HIV-positive women have a higher risk of cervical cancer than the general population. Nearly 18 million women have been found to be HIV positive globally, HIV weakens the immune system, increasing the likelihood of cervical cancer. Women with HIV are more likely to be diagnosed with cervical cancer because the CD4 protein count decreases. According to a survey conducted by the National Cancer Institute, a person with HIV is three times more likely to be diagnosed with cervical cancer.
The cervical cancer drug market is experiencing a number of significant trends that aid in efficient and targeted treatment of the disease, including advances in drug delivery. One such trend is the use of drugs that can be administered directly from the vagina, such as drugs that use vaginal formulations such as gels, creams, pessaries, rings, films and tablets. These drugs facilitate localized treatment of cervical cancer. The formulation of these drugs is such that they are easily absorbed into the vaginal tissue and reach the site of action. For example, companies have introduced vaginal gels such as Cidofovir and gel 851B Gel on the market for the treatment of cervical cancer. According to reports from the Clinical Trials Registry of the International Council for the Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), 851B The gel is being tested. While the Cidofovir gel, sold under the Vistide brand, is already a hit on the market. In addition to the gels mentioned above, drugs such as ISA101, AGEN2034 and Z-100 are in the pipeline and promise growth in the cervical cancer drug market.
Lack of awareness and other misconceptions about cervical cancers hinder the growth of the market for cervical cancer drugs. Many cervical cancer deaths among women are due to late diagnosis of the disease. Lack of awareness leads to avoiding the disease; this ignorance leads to delayed diagnosis and medication / treatment. According to a study conducted at Bowen University Teaching Hospital (BUTH), a Nigeria, about 318 women in the general practice were interviewed to assess the level of awareness of cervical cancer. The awareness level for cervical cancer was 22.6% and 17.9% for screening tests, with the main sources of information coming from healthcare talks and hospital staff.
In January 2019Bristol-Myers Squibb, an American biopharmaceutical company acquired Celgene for 74 billion dollars. This acquisition will allow Bristol-Myers Squibb to hold a strong position in the drug market in oncology, immunology and inflammation and cardiovascular disease. Celgene is an American biopharmaceutical company that discovers, develops and markets therapies for the treatment of cancer and inflammatory diseases globally.
Scope of the report
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. Track historical and expected market growth by geographic area.
The Market Characteristics section of the report defines and explains the market.
The market size section provides market size ($ b) covering both historical market growth and the impact of the COVID-19 virus and predicting its recovery.
Market segmentations divide the market into sub-markets.
The regional and country breakdowns section provides an analysis of the market in each geographic area and the size of the market by geographic area and compares their historical and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, major developed countries and major emerging markets.
The competitive landscape provides a description of the competitive nature of the market, market shares and a description of leading companies. The main financial transactions that have shaped the market in recent years are identified.
The trends and strategies section analyzes the shape of the market emerging from the crisis and suggests how companies can grow as the market picks up.
For more information on this report, please visit https://www.researchandmarkets.com/r/yasiu4
Research and Markets
Laura WoodChief director
For EST office hours Call + 1-917-300-0470
For US / CAN call toll free + 1-800-526-8630
For GMT office hours Call + 353-1-416-8900
Fax USA: 646-607-1907
Fax (outside the US): + 353-1-481-1716
View original content: https://www.prnewswire.com/news-releases/global-30-billion-cervical-cancer-drugs-market-2022-2026—pipeline-drugs-isa101-agen2034-and-z – 100-advance-to-lead-the-market-301606904.html
SOURCE Research and Markets